Things have been quiet, but for a reason:
they had a session with the FDA, wherein they were asked to provide additional information, which is now being compiled. Pending some decision from the FDA or something specific to announce, there is nothing to report other than published articles and reports, usually by others.
There have been some of those, but there was no reaction because they are not that easy to understand. Suffice it to say that in one article Onconase was deemed a potent new drug in the treatment of cancer (not an exact quote).
Alfacell will present at the ASCO conference this month:
Oral Presentations - Phase III Randomized Trial of Onconase (ONC) vs. Doxorubicin
(DOX) in Patients (Pts) with Unresectable Malignant Mesothelioma (UMM): Analysis of
Survival. - N Vogelzang, R Taub, D Shin, J Costanzi, H Pass, J Gutheil, M Georgiadis, P
McAndrew, K Kelly, H Chun, A Mittelman, S McCachren, K Shogen, S Mikulski, Univ of
Chicago, Chicago, IL; Columbia Univ, New York, NY; M D Anderson Cancer Ctr,
Houston, TX; Lone Star Oncology, Austin, TX; Wayne State Univ, Detroit, MI; Sidney
Kimmel Cancer Ctr, San Diego, CA; Allegheny Cancer Ctr, Pittsburgh, PA; Cedar Sinai
Medical Ctr, Los Angeles, CA; Univ of Colorado, Denver, CO; New York Medical Coll,
Valhalla, NY; Thompson Cancer Survival Ctr, Knoxsville, TN; Alfacell Corp, Bloomfield,
NJ.
Monday 5/22/00, 3:45 PM - 4:00 PM Ernest N. Morial Convention Center , La Nouvelle
Ballroom (Escalator 4)
Session Title: Mesothelioma and Small Cell Lung Cancer |
